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Abstract

Background: Previous studies have shown that patients with
epilepsy (PWE) perceived significant disruption in the quality
and provision of care due to the coronavirus disease 2019
(COVID-19) pandemic. The present study aimed to investigate
the effect of this pandemic on seizure control status and changes
in seizure frequency in PWE.
Methods: A consecutive sample of adult PWE registered in the
database of Shiraz Epilepsy Center (Shiraz, Iran) was included
in the study. In July 2021, phone interviews were conducted with
all selected patients. Information such as age, sex, last seizure,
seizure type, and frequency during the 12 months before the
study, and history of COVID-19 contraction was extracted. The
seizure control status of the patients in 2019 (pre-pandemic) was
compared with that during the COVID-19 pandemic. Data were
analyzed using SPSS software with the Fisher’s exact test and
Pearson’s Chi squared test. P<0.05 was considered statistically
significant.
Results: A total of 158 patients were included in the study, out of
which 62 (39.2%) patients had a stable seizure control status, 47
(29.7%) had fewer seizures, and 50 (31.6%) had more seizures.
Breakthrough seizures were reported by 32 (34.4%) patients.
Seizure frequency increased in 18 (27.7%) and decreased in 46
(70.7%) patients.
Conclusion: Overall, the COVID-19 pandemic has not been a
major precipitating factor nor has it affected the seizure control
status of PWE. In treated epilepsy, a fluctuating course with
periods of seizure freedom followed by relapses is part of its
natural history.
Please cite this article as: Asadi-Pooya AA, Nabavizadeh SA, Farazdaghi M. Effect
of the COVID-19 Pandemic on Seizure Control Status in Patients with Epilepsy.
Iran J Med Sci. 2022;47(6):588-593. doi: 10.30476/IJMS.2022.94056.2532.

What’s Known
•
During the COVID-19 pandemic,
people with epilepsy have perceived
more psychological distress than healthy
individuals, and cases with new-onset
focal seizures, serial seizures, and status
epilepticus have been reported in the
literature.

What’s New
•
Overall, the COVID-19 pandemic has
not been a major precipitating factor and
has not affected the seizure control status
of patients with epilepsy.
•
In treated epilepsy, a fluctuating course
with periods of seizure freedom followed by
relapses is part of its natural history.
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Introduction
Epileptic seizures often occur spontaneously without any
apparent cause or trigger, but many patients believe that seizures
are precipitated by external or internal stimuli. Some of these
precipitating factors have been well defined, including sleep
deprivation, premature awakening, and photic stimulation.1
The world has recently experienced a pandemic of the novel
coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2).2 The virus
has a high transmission potential; therefore, the implementation
of social distancing measures has been advocated worldwide
to control its outbreak. Iran reported its first confirmed cases
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of SARS-CoV-2 infection on 19 February 2020,
and the first wave of the COVID-19 pandemic
occurred in March-April 2020.3 In response to
the pandemic, a lockdown was initiated, and
the government canceled all public events,
closed schools, universities, shopping centers,
holy shrines, and banned all festivities. Soon
after, a ban on intercity travel was introduced
following an increase in the number of newly
infected cases.3
The outbreak of COVID-19 has created a
lot of stress and anxiety among people and
has disrupted many businesses, including the
provision of health care services.4-6 During the
COVID-19 pandemic, patients with epilepsy
(PWE) have experienced more psychological
distress than healthy individuals, and cases of
new-onset focal seizures, serial seizures, and
status epilepticus have been reported in the
literature.4 Previous studies indicated that PWE
perceived significant disruption in the quality
and provision of health care services (31%95%), increased stress and social isolation, and
increased seizure frequency (6%-35%) during
the COVID-19 pandemic.7-11 However, the
reported effect on seizure frequency in previous
studies were based on patients’ perceptions
and binary (yes/no) surveys. Hence, the present
study aimed to investigate the effect of the
COVID-19 pandemic on seizure control status
and changes in seizure frequency in PWE. We
also investigated the occurrence of breakthrough
seizures in PWE with well-controlled epilepsy.
We hypothesized that the COVID-19 pandemic
has been a major precipitating factor and has
negatively affected the seizure control status of
PWE.
Patients and Methods
A consecutive sample of 200 adult PWE
with focal epilepsy or idiopathic generalized
epilepsy (IGE) was included in the study based
on the duration of follow-up and in a retrograde
fashion. These patients were registered in the
database of Shiraz Epilepsy Center (Shiraz,
Iran). The inclusion criterion was at least three
years of follow-up at the center. Exclusion
criteria were patients with impaired awareness,
myoclonic seizures, focal seizures without
impaired awareness, not willing to participate,
and those with incomplete files. Out of the
selected adult PWE, a total of 100 patients with
no seizures in 2019 were arbitrarily selected
to investigate breakthrough seizures during
the pandemic. In addition, 100 patients with
at least two seizures in 2019 were recruited to
investigate changes in seizure frequency during
Iran J Med Sci November 2022; Vol 47 No 6

the pandemic. However, we could not evaluate
all the patients due to the limited workforce.
Eventually, 158 patients were included in the
study, out of which 93 belonged to the seizurefree and 65 to the not seizure-free category.
Written informed consent was obtained from all
the participants. The study was approved by the
Institutional Review Board of Shiraz University
of Medical Sciences, Shiraz, Iran (IR.SUMS.
REC.1400.608).
Data Collection
The data registered at the epilepsy center
database included age (at seizure onset,
diagnosis, and follow-up), sex, seizure type,
frequency, and final diagnosis. Due to the
confidentiality regulations of Shiraz University
of Medical Sciences, patients’ data may not be
shared.
Phone interviews with all 158 patients were
conducted in July 2021, and the following
information was extracted: age, sex, last
seizure, seizure type, and frequency during the
12 months prior to the start of the study (from
July 10th, 2020 to July 9th, 2021), and history of
COVID-19 contraction. The interview guide is
presented in table 1.
Statistical Analysis
Data were analyzed using SPSS software,
version 25.0 (IBM Corp., Armonk, N.Y., USA).
Based on the normality criterion, continuous
variables were expressed as mean±SD or
median/interquartile range (IQR). Categorical
variables were expressed as numbers and
percentages. Fisher’s exact test and Pearson’s
Chi squared test were used for statistical
analyses. P values (2-sided) less than 0.05 were
considered statistically significant.
Results
During the study period, a total of 3,737 patients
registered at Shiraz Epilepsy Center, of which
158 patients out of the eligible 200 individuals
were included in the study. The inclusion rate
was determined at 79% due to missing data in
42 cases. Of these participants, 93 (58.9%) were
seizure-free and 65 (41.1%) were not seizurefree in 2019 (pre-pandemic era). In terms of
seizure control, 62 (39.2%) patients had a stable
status (seizure-free=61, not seizure-free=1). The
remaining patients had varying seizure control
status, namely, 47 (29.7%) had fewer seizures,
and 50 (31.6%) had more seizures. Figure 1
shows the effect of the COVID-19 pandemic on
seizure control status in these patients (focal
epilepsy vs. IGE).
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Table 1: The phone interview guide
Interview guide
1
How old are you? What is your sex?
2
When was your last seizure?
3
Have you had seizures with staring and impaired awareness (without significant stiffness and body movements)
recently? How many times during the past year?
4
Have you recently had severe seizures with stiffness and body movements? How many times during the past year?
5
Have you contracted COVID-19?
If yes, how severe was it?
● Without signs and symptoms
● With mild symptoms
● Were hospitalized
6
Have your seizures become more frequent after contracting COVID-19?

impaired awareness were reported by 32 (34.4%)
patients during the study period. The frequency
of seizures during this period was 16 (IQR: 26;
range: 1-52), where three patients had only one
seizure, and 11 patients had 30 or more seizures.
As stated by seizure-free patients, 8 (8.6%)
contracted COVID-19 during the pandemic,
but symptoms were mild, and hospitalization
was not required. Breakthrough seizures and
seizures-free periods were reported by three
and five patients, respectively (Fisher’s exact
test: P>0.99, df: 1).

Figure 1: Effect of the COVID-19 pandemic on seizure
control status in patients with epilepsy. Thirty-two patients
had breakthrough seizures, and 24 patients became
seizure-free. df: Degree of freedom

Seizure-free Patients
The seizure-free category included 56
(60.2%) female and 37 (39.8%) male patients.
The mean age of these patients was 33±11 years
(range: 18-69 years), and their mean follow-up
duration was 7.8 years (median: 9, IQR: 6, range:
3-13 years). Focal epilepsy was diagnosed in 63
(67.7%) patients, and IGE was diagnosed in 30
(32.3%) patients. Breakthrough seizures with
590

Not Seizure-free Patients
The not seizure-free category included 32
(49.2%) female and 33 (50.8%) male patients.
The mean age of these patients was 33±11 years
(range: 18-61 years), and their mean follow-up
duration was 7.8 years (median: 9, IQR: 1, range:
3-10 years). Focal epilepsy was diagnosed in 49
(75.4%) patients, and IGE was diagnosed in 16
(24.6%) patients. The mean number of seizures
before the COVID-19 pandemic was 55 per year
(median: 18, IQR: 46, range: 2-730 seizures).
Whereas the mean number of seizures during the
pandemic was 16 per year (median: 4, IQR: 30,
range: 0-90 seizures). Seizure frequency status
during the pandemic compared to pre-pandemic
increased in 18 (27.7%) patients (negative change),
unchanged in 1 (1.5%) patient, and decreased in
46 (70.7%) patients (positive change). The number
of patients who became seizure-free during the
previous 12 months, was 24 (36.9%). The mean
change in seizure frequency was -39 per year
(median: -9; range: -640 to -40; IQR: 53).
As stated by not seizure-free patients, 2 (3.1%)
contracted COVID-19 during the pandemic but
did not require hospitalization, as the symptoms
were mild. Neither patient reported an increase
in seizure frequency after contracting COVID-19.
Discussion
In the present study, we observed that PWE
have experienced different seizure control
Iran J Med Sci November 2022; Vol 47 No 6

COVID-19 and epilepsy

status scenarios during the COVID-19
pandemic compared to the pre-pandemic era. In
approximately 40% of the patients, seizure control
status remained stable, whereas 30% reported
a positive change and 30% a negative change.
In a previous study of 456 PWE, worsened and
improved seizure control status was reported
in 67 and 61 patients, respectively.10 Since the
authors did not specify details of their findings,
it was not possible to draw a comparison with
our results. In another study of 189 patients
with a short follow-up period of two months, 16
patients reported a change in seizure frequency
(an increase in eight patients and a decrease
in eight other patients).12 In general, 6% to
35% of PWE perceived an increase in seizure
frequency since the start of the pandemic.7-11, 13, 14
A systematic review found a causal relationship
between psychological stress and seizure
worsening (during the COVID-19 pandemic)
without considering temporality.15
A study in 2012 investigated the patterns of
treatment response in newly diagnosed epilepsy
in 1,098 patients.16 The seizure outcomes
were categorized into four patterns, namely
(A) early and sustained seizure freedom, (B)
delayed but sustained seizure freedom, (C)
fluctuating between periods of seizure freedom
and relapse, and (D) seizure freedom never
attained. The outcome pattern A was observed
in 37%, B in 22%, C in 16%, and D in 25% of
the patients.16 In another study of 159 patients,
who were seizure-free for the first five years
after resection epilepsy surgery, 32 (20%)
patients had at least one recurrent seizure
during follow-up.17 Therefore, it is very common
for treated epilepsy to fluctuate between
periods of seizure freedom and relapse. As
a result, reported findings in previous studies
about seizure worsening during the COVID-19
pandemic, including our previous study,7-11, 13, 14
should not be attributed to the pandemic period
nor to SARS-CoV-2 infection. It is simply part of
the natural history of treated epilepsy to observe
improvement or deterioration in seizure control
status over time, at least in many patients.
Similar to our results, two other studies10, 12
reported an equal number of patients with
seizure worsening and improvement during the
COVID-19 pandemic. Clearly, a severe illness
due to COVID-19 may precipitate seizures in
PWE and even in healthy individuals.4 Seizures
in patients with SARS-CoV-2 infection may
occur due to a variety of reasons, including
fever, neurotropism, hypoxia, multiorgan
failure, and so on.18 However, seizures are a
rare presenting symptom of COVID-19.19 It
is noteworthy that PWE is no more prone to
Iran J Med Sci November 2022; Vol 47 No 6

contracting COVID-19 than other individuals,
and COVID-19 in PWE is not associated with a
more severe illness or a poorer prognosis.20, 21
In the current study, despite the low sample
size, we did not observe any indication of
worsening seizure control status in PWE due to
COVID-19 contraction.
Finally, it is important to highlight that
restructuring of health care services to cope with
the COVID-19 pandemic resulted in the closure
of epilepsy/neurology clinics and epilepsy
monitoring units in many countries.22 Recently,
international organizations (e.g., the International
League Against Epilepsy and the International
Federation of Clinical Neurophysiology) have
called for the continued functioning of Epilepsy
Monitoring Units (EMUs) during emergency
situations, such as the COVID-19 pandemic.
Long-term video-EEG monitoring is an essential
diagnostic service. It is also requested that
access to video-EEG monitoring of the patients
in the EMUs must be given high priority.22
Similarly, epilepsy/neurology clinics should be
considered essential and should continue to
serve the patients, at least in the form of virtual
communication.
The main limitations of the study were the low
sample size and a single-center study design.
Besides, our patients did not routinely keep a
seizure journal (diary), and the stated seizure
frequency was based on their recollections.
Conclusion
Overall, the COVID-19 pandemic has not been
a major precipitating factor affecting seizure
control status in PWE. In many patients, it is the
natural history of treated epilepsy to fluctuate
between periods of seizure freedom and relapse.
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